Skip to content

Probiotic Supplementation During Pregnancy in Preeclampsia High-risk Groups

Effects of Probiotic Supplementation During Pregnancy on Maternal and Infant Outcomes in Preeclampsia High-risk Groups Based on Abnormal Intestinal Flora: a Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05554185
Enrollment
338
Registered
2022-09-26
Start date
2022-09-21
Completion date
2024-12-31
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy

Brief summary

In this randomized controlled study, preventive intervention of aspirin combined with probiotics or aspirin combined with placebo would given to PE (pre-eclampsia) high-risk population with gut microbiota dysbiosis during their pregnancy, and finally assess the efficacy and safety of aspirin combined with probiotics to prevent PE.

Interventions

DIETARY_SUPPLEMENTaspirin 100mg and probiotics 1 bag

taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* PE high-risk population aged 18-50 years with gut microbiota dysbiosis * No severe cardiopulmonary diseases * No severe hepatic and renal insufficiency * No severe active infection * Pregnant women did not take antibiotics or antifungal drugs 30 days before fecal sample collection; No probiotic preparation was taken 2 weeks before sample collection; Never take drugs that may interfere with glucose and lipid metabolism * No diseases affecting intestinal microecology * No history of smoking and drinking * The researchers evaluated those pregnant women expected to deliver more than 20 weeks * Voluntarily participate in this clinical study and sign the informed consent form

Exclusion criteria

* With severe cardiopulmonary, hepatic and renal insufficiency * With uncontrolled active infections 2 weeks before enrollment * Subjects took antibiotics or antifungal drugs 30 days before sample collection; Take probiotics 2 weeks before sample collection; Have taken drugs that may interfere with glucose and lipid metabolism * with diseases affecting intestinal microecology * Smoking and drinking history * With acute gastrointestinal ulcer * Hemorrhagic constitution * Other discomfort assessed by the investigato

Design outcomes

Primary

MeasureTime frameDescription
The incidence of preeclampsiaFrom being recruited to 6 weeks after deliveryAfter 20 weeks of pregnancy, systolic blood pressure ≥ 140mmHg and / or diastolic blood pressure ≥ 90mmHg, accompanied by any of the following items: urinary protein ≥ 0.3g/24h, or urinary protein / creatinine ratio ≥ 0.3,or random urinary protein ≥ (+) (examination method for unconditional protein quantification); Non-albuminuria can be accompanied by any kind of organ or system involvement: heart, lung, liver, kidney and other important organs, or abnormal changes in blood system, digestive system, nervous system, placenta-fetus, etc.

Secondary

MeasureTime frameDescription
The incidence of fetal growth restrictionFrom being recruited to 6 weeks after deliverydue to the influence of pathological factors such as mother, fetus and placenta, fetal growth does not reach its due genetic potential, which is characterized by fetal body weight or abdominal circumference estimated by ultrasound lower than the 10th percentile of the corresponding gestational age

Contacts

Primary ContactYichi Zhang
1525683944@qq.com18774562132

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026